0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Integrin alpha D beta 2

Integrin alpha D beta 2

Brief Information

Name:Integrin alpha-4
Target Synonym:CD49D,Integrin alpha-IV,ITGA4,Integrin Subunit Alpha 4,Alpha 4 Subunit Of VLA-4 Receptor,VLA-4 Subunit Alpha,Integrin, Alpha 4 (Antigen CD49D, Alpha 4 Subunit Of VLA-4 Receptor),CD49 antigen-like family member D,Very Late Activation Protein 4 Receptor, Alpha 4 Subunit,Antigen CD49D, Alpha-4 Subunit Of VLA-4 Receptor,Integrin Alpha-4,269C Wild Type,CD49d Antigen,Antigen CD49D,IA4,Integrin alpha4
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

Product ListCompare or Buy

Par statut du produit :
Par catégorie de produit :
Par espèce :
Par étiquette :
Par conjugaison :
Cat . Non Espèces Description du produit Structure Pureté Caractéristique
IT2-H53W6 Human Human Integrin alpha D beta 2 (ITGAD&ITGB2) Heterodimer Protein, His Tag&Tag Free
IT2-H53W6-structure
IT2-H53W6-sds
ACRO Quality

Part of Bioactivity data

IT2-H53W6-MALS-HPLC
 Integrin alpha D beta 2 ELISA

Immobilized Human ITGAD&ITGB2 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT2-H53W6) at 1 μg/mL (100 μL/well) can bind Human Integrin beta 2/CD18 Antibody with a linear range of 0.3-5 ng/mL (QC tested).

Synonym Name

Integrin alpha D beta 2,ITGAD & ITGB2

Background

Integrin alpha-D/beta-2 is a receptor for ICAM3 and VCAM1. May play a role in the atherosclerotic process such as clearing lipoproteins from plaques and in phagocytosis of blood-borne pathogens, particulate matter, and senescent erythrocytes from the blood. Contributes to natural killer cell cytotoxicity. Involved in leukocyte adhesion and transmigration of leukocytes including T-cells and neutrophils. Triggers neutrophil transmigration during lung injury through PTK2B/PYK2-mediated activation (PubMed:18587400). Alpha D beta 2, selectively binds ICAM-3 and does not appear to bind ICAM-1. In addition, a soluble form of alpha D beta 2 binds VCAM-1 with greater efficiency relative to ICAM-3. The I domain of alpha D contains a binding site for VCAM-1 since recombinant alpha D I domain binds specifically to VCAM-1.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Natalizumab biosimilar(Polpharma Biologics) PB-006; DST-356A1 Approved Polpharma Biologics Sa Tyruko United States Crohn Disease; Multiple Sclerosis Sandoz Inc 2023-08-24 Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Crohn Disease Details
Natalizumab biosimilar(Polpharma Biologics) PB-006; DST-356A1 Approved Polpharma Biologics Sa Tyruko United States Crohn Disease; Multiple Sclerosis Sandoz Inc 2023-08-24 Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Crohn Disease Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ATL-1102 ATL-1102; ATL/TV-1102; ISIS-107248; TV-1102 Phase 2 Clinical Ionis Pharmaceuticals Inc Multiple Sclerosis; Muscular Dystrophy, Duchenne Details
BIIB-107(Biogen) BIIB-107 Phase 1 Clinical Biogen Inc Multiple Sclerosis Details
ELND-004 ELND-004 Phase 1 Clinical Perrigo Company Plc Autoimmune Diseases Details
ATL-1102 ATL-1102; ATL/TV-1102; ISIS-107248; TV-1102 Phase 2 Clinical Ionis Pharmaceuticals Inc Multiple Sclerosis; Muscular Dystrophy, Duchenne Details
BIIB-107(Biogen) BIIB-107 Phase 1 Clinical Biogen Inc Multiple Sclerosis Details
ELND-004 ELND-004 Phase 1 Clinical Perrigo Company Plc Autoimmune Diseases Details

This web search service is supported by Google Inc.

totop

Laisser un message